China Resources Pharmaceutical Group (03320.HK) plans to participate in the establishment of a fund.

Noted on the CITIC Financial Management APP, CR Pharmaceutical (03320.HK) announced that CR Pharmaceutical (Shantou), CR Double Crane, Double Crane (Beijing), CR Pharmaceutical Investment (each being a subsidiary of the Company) are in negotiations with Hanwei Huayou Shantou and other potential partners to establish a fund with an expected size of 500 million Chinese yuan. The fund is expected to primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total expected amount of capital not exceeding 123 million Chinese yuan, accounting for approximately 24.6% of the total expected commitment of the fund. It is expected that Shenzhen CR Capital will be entrusted as the fund manager for the fund after its establishment.